Holen Sie sich die Stockscreener-App
7.09
2.61%
-0.19
Handel nachbörslich:
7.12
0.03
+0.42%
Schlusskurs vom Vortag:
$7.28
Offen:
$7.22
24-Stunden-Volumen:
2.88M
Relative Volume:
0.66
Marktkapitalisierung:
$1.33B
Einnahmen:
$42.73M
Nettoeinkommen (Verlust:
$-204.38M
KGV:
-5.8479
EPS:
-1.2124
Netto-Cashflow:
$-189.73M
1W Leistung:
+7.10%
1M Leistung:
-45.96%
6M Leistung:
-1.80%
1J Leistung:
+17.58%
1-Tages-Spanne:
$7.04
$7.495
1-Wochen-Bereich:
$6.61
$7.80
52-Wochen-Spanne:
$5.02
$21.73
Wave Life Sciences Ltd Stock (WVE) Company Profile
Firmenname
Wave Life Sciences Ltd
Sektor
Branche
Telefon
617-949-2900
Adresse
7 STRAITS VIEW, SINGAPORE
Compare WVE vs VRTX, REGN, ARGX, ALNY, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
WVE
Wave Life Sciences Ltd
|
7.09 | 1.37B | 42.73M | -204.38M | -189.73M | -1.2124 |
VRTX
Vertex Pharmaceuticals Inc
|
434.30 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
763.04 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
748.25 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
330.34 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
163.81 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Wave Life Sciences Ltd Stock (WVE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-05 | Eingeleitet | BofA Securities | Buy |
| 2025-12-12 | Bestätigt | Wedbush | Outperform |
| 2025-12-09 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2025-10-20 | Eingeleitet | Wells Fargo | Overweight |
| 2025-08-04 | Eingeleitet | Canaccord Genuity | Buy |
| 2025-07-28 | Eingeleitet | Oppenheimer | Outperform |
| 2025-07-16 | Eingeleitet | Citigroup | Buy |
| 2025-06-11 | Fortgesetzt | Raymond James | Outperform |
| 2025-04-29 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2025-04-08 | Eingeleitet | Wedbush | Outperform |
| 2025-02-25 | Eingeleitet | Jefferies | Buy |
| 2024-10-16 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2024-09-27 | Fortgesetzt | JP Morgan | Overweight |
| 2024-09-19 | Eingeleitet | B. Riley Securities | Buy |
| 2024-09-09 | Eingeleitet | JP Morgan | Overweight |
| 2024-05-15 | Eingeleitet | Wells Fargo | Overweight |
| 2023-12-19 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2023-07-05 | Eingeleitet | Raymond James | Outperform |
| 2023-05-24 | Herabstufung | Jefferies | Buy → Hold |
| 2020-12-15 | Fortgesetzt | H.C. Wainwright | Buy |
| 2020-10-23 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2019-12-31 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2019-11-01 | Eingeleitet | Guggenheim | Buy |
| 2019-07-15 | Eingeleitet | Cowen | Market Perform |
| 2019-04-17 | Bestätigt | H.C. Wainwright | Buy |
| 2018-08-07 | Eingeleitet | Stifel | Buy |
| 2018-07-23 | Eingeleitet | H.C. Wainwright | Buy |
| 2018-03-19 | Bestätigt | Mizuho | Buy |
| 2017-02-15 | Eingeleitet | H.C. Wainwright | Buy |
| 2016-11-10 | Fortgesetzt | Leerink Partners | Outperform |
| 2015-12-07 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2015-12-07 | Eingeleitet | Jefferies | Buy |
| 2015-12-07 | Eingeleitet | Leerink Partners | Outperform |
| 2015-12-07 | Eingeleitet | Sun Trust Rbsn Humphrey | Buy |
Alle ansehen
Wave Life Sciences Ltd Aktie (WVE) Neueste Nachrichten
A Look At Wave Life Sciences (WVE) Valuation After INLIGHT Phase 1 Obesity Data Disappoints Investors - simplywall.st
Wave Life Sciences (WVE) Is Up 14.4% After Phase 1 Data On Long‑Acting Obesity Drug WVE‑007 - simplywall.st
Wave Life Sciences Ltd. (WVE) stock price, news, quote and history - Yahoo Finance Singapore
WVE.O PE Ratio & Valuation, Is WVE.O Overvalued - Intellectia AI
Wave Life Sciences Ltd. (WVE) Stock Price, News, Quote & History - Yahoo! Finance Canada
Gold Royalty, Wave Life Sciences, and More Stocks See Action From Activist Investors -- Barrons.com - moomoo.com
Wave Life Sciences plunges after early-stage data for obesity therapy - MSN
Wave Life Sciences Ltd. (WVE) PT increased to $52 at Canaccord following pipeline review - MSN
WVE.O Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
WVE.O Technical Analysis & Stock Price Forecast - Intellectia AI
Wave Life Sciences’ Weight Loss Drug Phase 1 Clinical Data Triggers Stock Volatility, Yet Differentiated Path Still Shows Promise - NAI500
Wave Life Sciences (WVE) Surges 9.5%: Is This an Indication of Further Gains? - qz.com
Wave Life Sciences Announces Positive Interim Phase 1 Data from INLIGHT: Further Improvements in Body Composition, with Clinically Meaningful Reductions in Visceral Fat and Waist Circumference, at Six Months Following Single Dose of WVE-007 - Investing News Network
Wells Fargo Maintains Wave Life Sciences(WVE.US) With Buy Rating, Cuts Target Price to $13 - Moomoo
WVE Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
JPMorgan Chase & Co. Has $6.30 Million Position in WAVE Life Sciences Ltd. $WVE - marketbeat.com
WVE posts interim data from phase I study on WVE-007, stock tanks - MSN
WAVE Life Sciences (NASDAQ:WVE) Shares Gap UpTime to Buy? - marketbeat.com
Wave Life Sciences Stock (WVE) Opinions on INLIGHT Trial Data - Moomoo
Wave Life Sciences Obesity Data Highlights Visceral Fat Focus Over Weight Loss - Yahoo Finance
[SCHEDULE 13D/A] Wave Life Sciences Ltd. Amended Major Shareholder Report - stocktitan.net
RA Capital boosts Wave Life Sciences (NASDAQ: WVE) stake with 8.8M-share open-market buy - stocktitan.net
Wave Life Sciences Ltd. (WVE) PT Increased to $52 at Canaccord Following Pipeline Review - Insider Monkey
WaVe Life Sciences Ltd (WVE) Stock Price Quote Today & Current Price Chart - Capital.com
Why is Wave Life Sciences stock falling after weight loss study data? - MSN
13 Best Stocks to Invest In on Robinhood for Beginners - Insider Monkey
Wave Life Sciences shares plunge 30% despite encouraging obesity trial results - msn.com
WVE Should I Buy - Intellectia AI
Wave hits 52-week low as analysts react to obesity drug data - msn.com
ARWR Stock Slid Lower Today — What Does Wave Life Sciences Have To Do With It? - Stocktwits
Can Wave Life Sciences’ (WVE) Visceral Fat Data Redefine Its Obesity Strategy Despite Modest Weight Loss? - simplywall.st
WAVE Life Sciences (NASDAQ:WVE) Stock Price Up 5.9%Time to Buy? - MarketBeat
Assessing Wave Life Sciences (WVE) Valuation After Volatile Reaction To WVE-007 Phase 1 Results - simplywall.st
Setback to Wave Life Sciences: Obesity Drug WVE-007 Shows Limited Efficacy in Early Trial - Medical Dialogues
Chances Slimmer For Wave’s WVE-007 After Lower BMI Patients Fail To Shift Weight - Citeline News & Insights
WVE Shares Preliminary Results from Phase I Trial of WVE-007, Stock Plummets - Bitget
INHBE inhibitions? Data from Wave send ripples - BioWorld MedTech
Wave Life Sciences Crashes Deep into Oversold Territory as Obesity Drug Data Disappoints. Should You Buy the Dip? - Barchart.com
WVE Posts Interim Data From Phase I Study on WVE-007, Stock Tanks - finance.yahoo.com
Bank of America Has Lowered Expectations for WAVE Life Sciences (NASDAQ:WVE) Stock Price - MarketBeat
Wave Life Sciences Slips as Obesity Data Fails to Convince - Yahoo Finance
Wells Fargo & Company Cuts WAVE Life Sciences (NASDAQ:WVE) Price Target to $13.00 - marketbeat.com
A Quick Look at Today's Ratings for Wave Life Sciences(WVE.US), With a Forecast Between $13 to $39 - Moomoo
Wave Life Sciences stock hits 52-week low at $5.27 By Investing.com - Investing.com Australia
Wedbush Cuts Price Target on Wave Life Sciences to $15 From $35, Keeps Outperform Rating - MarketScreener
RBC Capital reiterates Wave Life Sciences stock rating on obesity data - Investing.com India
Risk-Adjusted Buy Rating on Wave Life Sciences: Differentiated Obesity Mechanism, Reset Valuation, and Long-Term Upside Despite 400 mg Uncertainty - TipRanks
Wave Life Sciences (WVE) Plummets 30% Following INLIGHT Obesity Trial Results - MEXC
Wave loses half its market cap on obesity data - biocentury.com
WAVE Life Sciences Shares Phase 1 WVE-007 Data Showing Visceral Fat Loss, Muscle Preservation Signal - MarketBeat
Wave Life Sciences Reports Positive Phase 1 Results for WVE-007 in Obesity, Showing Significant Visceral Fat Reduction and Muscle Preservation at 6 Months 123 - Minichart
Finanzdaten der Wave Life Sciences Ltd-Aktie (WVE)
Umsatz
Nettogewinn
Free Cashflow
ENV
Wave Life Sciences Ltd-Aktie (WVE) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | Director |
Mar 27 '26 |
Buy |
6.43 |
2,495,623 |
16,046,856 |
26,004,414 |
| RA CAPITAL MANAGEMENT, L.P. | Director |
Mar 30 '26 |
Buy |
6.50 |
971,091 |
6,312,092 |
26,975,505 |
| Francis Chris | See Remarks |
Feb 26 '26 |
Option Exercise |
4.28 |
33,194 |
141,920 |
79,767 |
| Francis Chris | See Remarks |
Feb 26 '26 |
Sale |
15.05 |
33,194 |
499,593 |
61,867 |
| Moran Kyle | Chief Financial Officer |
Feb 09 '26 |
Sale |
13.45 |
3,588 |
48,259 |
134,385 |
| BOLNO PAUL | President and CEO |
Feb 09 '26 |
Sale |
13.45 |
10,480 |
140,956 |
275,520 |
| Francis Chris | See Remarks |
Feb 09 '26 |
Sale |
13.45 |
1,883 |
25,326 |
61,867 |
| Vargeese Chandra | See Remarks |
Feb 09 '26 |
Sale |
13.45 |
3,228 |
43,417 |
408,246 |
0.87%
0.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):